Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
News|Videos|December 17, 2024
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Author(s)Steven M. Horwitz, MD
Steven Horwitz, MD, presents the final results of the Phase 2 PRIMO trial, highlighting the efficacy and safety of duvelisib as a promising treatment option for relapsed/refractory peripheral T-cell lymphoma, with insights into overall response rates, progression-free survival, and adverse event management.
Advertisement
Advertisement
Related to this article
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5